CHICAGO — Three companies presented Phase 1 clinical trial results on new CAR-T therapies for multiple myeloma on Sunday at the American Society of Clinical Oncology in Chicago. Each offered innovations on the current generation of approved myeloma CAR-T therapies, ide-cel and cilta-cel, with promising — if early – results.
“It’s good to see the early data,” said Saad Usmani, the chief of myeloma service at Memorial Sloan Kettering, who did not work on any of the studies but did work on Janssen’s cilta-cel. “We’re getting into second- and third-generation CARs now with faster production times.”